Hematopoietic and Lymphoid Cell Neoplasm

In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC)

PMID 12483530 · Rowley et al., 2002 · Open in CIViC

In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC)

PMID 16497971 · Hoang et al., 2006 · Open in CIViC

In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015).

PMID 19284554 · Greco et al., 2009 · Open in CIViC

Activating mutations in KRAS or NRAS were observed more frequently in multiple myeloma patients than in patients with monoclonal gammopathy of uncertain significance (MGUS) (31% vs. 5% ). Another stu… (full text at CIViC)

PMID 11524732 · Bezieau et al., 2001 · Open in CIViC

In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015).

PMID 19284554 · Greco et al., 2009 · Open in CIViC

Activating mutations in KRAS or NRAS were observed more frequently in multiple myeloma patients than in patients with monoclonal gammopathy of uncertain significance (MGUS) (31% vs. 5% ). Another stu… (full text at CIViC)

PMID 11524732 · Bezieau et al., 2001 · Open in CIViC

In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015).

PMID 19284554 · Greco et al., 2009 · Open in CIViC

Activating mutations in KRAS or NRAS were observed more frequently in multiple myeloma patients than in patients with monoclonal gammopathy of uncertain significance (MGUS) (31% vs. 5% ). Another stu… (full text at CIViC)

PMID 11524732 · Bezieau et al., 2001 · Open in CIViC

In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutations in KRAS (22/28 in G12/G13). Those with KRAS (but not NRAS) mutations had worse overall (me… (full text at CIViC)

PMID 18528420 · Chng et al., 2008 · Open in CIViC

Plays a causative role in leukemogenesis. RAS existed in a GTP-bound state in greater abundance than wild type, leading to increased phosphorylation of ERK (Fig. 2) Identified as oncogenic alleles in … (full text at CIViC)

PMID 19075190 · Tyner et al., 2009 · Open in CIViC

This study performed exome sequencing on 55 DLBCL tumor samples and identified several significantly mutated genes including KRAS.

PMID 22343534 · Lohr et al., 2012 · Open in CIViC

In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutaions in KRAS. Those with mutations had worse overall and progression free survival than those wi… (full text at CIViC)

PMID 18528420 · Chng et al., 2008 · Open in CIViC

This retrospective study included 1389 cases of high-risk pediatric B-ALL, of which 284 were identified by TaqMan Low Density Array to have a BCR-ABL1-like (Ph-like) gene expression signature. RT-PCR … (full text at CIViC)

PMID 28408464 · Reshmi et al., 2017 · Open in CIViC

This retrospective study reported the outcome of 24 patients with Ph-like acute lymphoblastic leukemia (Ph-like ALL) harboring ABL-class fusions who were treated with a combination of tyrosine kinase … (full text at CIViC)

PMID 31434701 · Tanasi et al., 2019 · Open in CIViC

The authors analyzed 304 primary DLBCLs using whole exome sequencing and targeted sequencing. This one one of the genes they identified as significantly enriched for somatic mutations.

PMID 29713087 · Chapuy et al., 2018 · Open in CIViC

The authors analyzed 304 primary DLBCLs using whole exome sequencing and targeted sequencing. This one one of the genes they identified as significantly enriched for somatic mutations. The rate of mut… (full text at CIViC)

PMID 29713087 · Chapuy et al., 2018 · Open in CIViC

The BCR-ABL1 expressing imatinib-resistant cell line MYL-R overexpresses LYN, an SRC family kinase. Dasatinib showed the most potency against MYL-R compared to the non-resistant MYL cell line (IC50: 6… (full text at CIViC)

PMID 18191450 · Deguchi et al., 2008 · Open in CIViC

The BCR-ABL1 expressing imatinib-resistant cell line MYL-R overexpresses LYN, an SRC family kinase. Nilotinib showed 3.1 times less potency than bafetinib (INNO-406) against MYL-R (IC50: 993.6 nM vs. … (full text at CIViC)

PMID 18191450 · Deguchi et al., 2008 · Open in CIViC

In an in vitro study, a K562 cell line expressing LYN Y508F mutation demonstrated sensitivity to axitinib treatment, comparable to K562 cells expressing wild-type LYN or vector. Sensitivity was determ… (full text at CIViC)

PMID 26912052 · Halbach et al., 2016 · Open in CIViC

In an in vitro study, a K562 cell line expressing LYN Y508F mutation demonstrated sensitivity to dasatinib treatment, comparable to K562 cells expressing wild-type LYN or vector. Sensitivity was deter… (full text at CIViC)

PMID 26912052 · Halbach et al., 2016 · Open in CIViC

The C121S/G128D and 56_61QKQKVG>R variants were resistant to the mitogen-activated protein kinase kinase (MEK) inhibitor trametinib in vitro. All three variant proteins constitutively phosphorylated E… (full text at CIViC)

PMID 25899310 · Nelson et al., 2015 · Open in CIViC

The C121S/G128D and 56_61QKQKVG>R variants were resistant to the mitogen-activated protein kinase kinase (MEK) inhibitor trametinib in vitro. All three variant proteins constitutively phosphorylated E… (full text at CIViC)

PMID 25899310 · Nelson et al., 2015 · Open in CIViC

Brown wt al. described ex vivo efficacy of MEK inhibition in tissue obtained from a LCH patient harboring this somatic MAP2K1 mutation. We have treated a single patient with a systemic LCH showing th… (full text at CIViC)

PMID 24982505 · Brown et al., 2014 · Open in CIViC

In this case series, 3 patients with Langerhans cell histiocytosis (LCH) were studied. Patient #1 was a 15-year-old male who has experienced five reactivations of LCH. He presented with left mastoid L… (full text at CIViC)

PMID 32991018 · Messinger et al., 2020 · Open in CIViC

In this preclinical study, the sensitivity of Multiple Myeloma tumors harboring 1q21 amplification to MCL-1 inhibitor S63845 was tested. The effect of the MCL-1 inhibitor was tested in 21 human myelom… (full text at CIViC)

PMID 31856269 · Slomp et al., 2019 · Open in CIViC

Clinically, high MECOM (EVI1) expression occurs in approximately 8% of patients with de novo AML. In AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2), aberrant MECOM expression is caused by a break poin… (full text at CIViC)

PMID 20308656 · Gröschel et al., 2010 · Open in CIViC

In this study, 17 patients with a variant pericentric inv(3) were identified from an institutional cytogenetics database, out of283 myeloid neoplasms with a MECOM rearrangement (MECOM-R) confirmed b… (full text at CIViC)

PMID 36672407 · Tang et al., 2023 · Open in CIViC

This study evaluates the frequency of MECOM rearrangements by fluorescence in situ hybridization (FISH) in 76 AML and 21 MDS patients with various 3q chromosomal aberrations. Patients were referred to… (full text at CIViC)

PMID 26815134 · Baldazzi et al., 2016 · Open in CIViC

t(3;21)(q26.2;q22) is a rare variant of AML, occurring in approximately 1% of cases. It carries a very poor prognosis with none of the reported patients surviving longer than 28 months and with an ave… (full text at CIViC)

PMID 22706870 · Li et al., 2012 · Open in CIViC

Multiple studies have demonstrated an enrichment for somatic missense mutations in MEF2B including multiple hot spots.

PMID 21796119 · Morin et al., 2011 · Open in CIViC

[the study] identified 25 significantly mutated genes, including known drivers such as ataxia-telangectasia mutated (ATM), cyclin D1 (CCND1), and the tumor suppressor TP53; mutated genes encoding the … (full text at CIViC)

PMID 24145436 · Beà et al., 2013 · Open in CIViC

The authors analyzed 304 primary DLBCLs using whole exome sequencing and targeted sequencing. This one one of the genes they identified as significantly enriched for somatic mutations.

PMID 29713087 · Chapuy et al., 2018 · Open in CIViC

This study was an international, multi-center retrospective analysis of 107 patients with MEF2D rearrangements, with information collected from 14 different regional study groups. The aim was to asses… (full text at CIViC)

PMID 36309560 · Ohki et al., 2023 · Open in CIViC

This study describes a cohort of 24 patients with BCR-ABL1-like B-ALL and ABL-class kinase rearrangement exposed to TKI frontline or at relapse, who showed favorable MRD response and outcome. Specific… (full text at CIViC)

PMID 31434701 · Tanasi et al., 2019 · Open in CIViC

Cell lines with MEF2D-CSF1R fusion show sensitivity to the tyrosine kinase inhibitors Imatinib and GW-2580.

PMID 24186003 · Lilljebjörn et al., 2014 · Open in CIViC